NCT05611905View on ClinicalTrials.gov

Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

December 22, 2023

Primary Completion Date

November 26, 2026

Study Completion Date

November 26, 2027

Conditions
Renal ExcretionBacterial InfectionsInflammatory DiseaseOncologic Disease
Interventions
COMBINATION_PRODUCT

11C-para-aminobenzoic acid PET/CT

A bolus of 20 mCi of 11C-PABA followed by PET/CT

DRUG

Probenecid

Oral dose of 500 mg (tablet) 2 hours before IV dose of 11C-PABA will be administered.

Trial Locations (1)

21218

RECRUITING

Johns Hopkins Medical Institutions, Baltimore

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Johns Hopkins University

OTHER